Technical Analysis for MGNX - MacroGenics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 1.18% | |
| Oversold Stochastic | Weakness | 1.18% | |
| NR7 | Range Contraction | 4.37% | |
| Narrow Range Bar | Range Contraction | 4.37% | |
| Stochastic Reached Oversold | Weakness | 4.37% | |
| Oversold Stochastic | Weakness | 4.37% | |
| Fell Below 20 DMA | Bearish | 0.23% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 6 hours ago |
| 20 DMA Resistance | about 9 hours ago |
| Up 5% | about 9 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
| Rose Above 10 DMA | about 10 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 08/07/2024
MacroGenics, Inc. Description
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Immune System Autoimmune Disease Antibodies Treatment Of Cancer Monoclonal Antibodies Monoclonal Antibody Antibody Novel Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.88 |
| 52 Week Low | 3.14 |
| Average Volume | 2,789,578 |
| 200-Day Moving Average | 10.16 |
| 50-Day Moving Average | 7.68 |
| 20-Day Moving Average | 4.45 |
| 10-Day Moving Average | 4.24 |
| Average True Range | 0.46 |
| RSI (14) | 36.71 |
| ADX | 32.29 |
| +DI | 24.64 |
| -DI | 33.82 |
| Chandelier Exit (Long, 3 ATRs) | 3.81 |
| Chandelier Exit (Short, 3 ATRs) | 5.37 |
| Upper Bollinger Bands | 4.99 |
| Lower Bollinger Band | 3.91 |
| Percent B (%b) | 0.36 |
| BandWidth | 24.29 |
| MACD Line | -0.80 |
| MACD Signal Line | -1.05 |
| MACD Histogram | 0.2547 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.74 | ||||
| Resistance 3 (R3) | 4.75 | 4.61 | 4.66 | ||
| Resistance 2 (R2) | 4.61 | 4.50 | 4.61 | 4.64 | |
| Resistance 1 (R1) | 4.46 | 4.43 | 4.54 | 4.45 | 4.61 |
| Pivot Point | 4.32 | 4.32 | 4.36 | 4.32 | 4.32 |
| Support 1 (S1) | 4.17 | 4.21 | 4.25 | 4.16 | 3.99 |
| Support 2 (S2) | 4.03 | 4.14 | 4.03 | 3.96 | |
| Support 3 (S3) | 3.88 | 4.03 | 3.94 | ||
| Support 4 (S4) | 3.87 |
